INTRODUCTION
============

Benign prostatic hyperplasia (BPH), characterized by enlargement of the prostate gland and narrowing of the urethra, affects \>50% of men older than 60 years and the majority older than 80 years, and is a major cause of lower urinary tract symptoms (LUTS).^[@R1],[@R2]^ LUTS can be obstructive and/or irritative, and can significantly affect quality of life.^[@R1],[@R2]^ BPH is the result of a nonmalignant proliferation of cells in the prostate gland, and although the etiology of the proliferation is not well understood, known factors associated with BPH are aging and androgen metabolism.^[@R3]^ Recent evidence has also suggested that metabolic disorders, including hyperinsulinemia, dyslipidemia, and obesity may play a role in the development of prostate hyperplasia.^[@R4]--[@R7]^

Metabolic syndrome (MS) is a cluster of medical conditions including hypertension, impaired glucose metabolism, abdominal obesity, hypertriglyceridemia, and low high-density lipoprotein cholesterol (HDL-C).^[@R8]^ The underlying feature of MS is insulin resistance, and MS is associated with an increased risk of type 2 diabetes mellitus and cardiovascular disease.^[@R8]^ Similar to BPH, the prevalence of MS increases with age.^[@R9]^ Furthermore, recent evidence is suggesting a link between MS and prostatic hyperplasia and LUTS.^[@R5],[@R10]--[@R13]^ In contrast with results from the United States and European countries, results from Asian populations have been inconsistent.^[@R1]^ One study indicated that MS was not clearly correlated with LUTS/BPH in Korean men in their 50s,^[@R1]^ whereas the results of another study indicated that MS was associated with an increased total volume and annual prostate growth rate.^[@R14]^ A recent meta-analysis indicated that patients with MS have a higher total prostate volume than those without MS, yet International Prostate Symptom Scores (IPSS) were not different between those with and without MS.^[@R15]^

As there are a number of different measures of determining BPH, the purpose of this meta-analysis was to examine the association of MS with measures of BPH including prostate growth rate, prostate volume, IPSS, prostate-specific antigen (PSA) level, and maximal flow rate.

MATERIALS AND METHODS
=====================

Literature Search and Study Selection
-------------------------------------

This systematic review and meta-analysis was performed in accordance with MOOSE guidelines.^[@R16]^ Medline, Cochrane, EMBASE, Google Scholar databases, and CBM were searched from inception until March 23, 2015 using combinations of the keywords: benign prostate hyperplasia/BPH, metabolic syndrome, total prostate volume, prostate growth rate, prostate specific antigen, International Prostate Symptom Score/IPSS, maximal flow rate. Inclusion criteria for the analysis were: cohort or case-controlled studies; patients had BPH with or without LUTS and were older than 18 years; compared patients with and without MS; quantitative outcomes of interest were reported. Letters, comments, editorials, case reports, proceedings, and personal communications were excluded, as were studies in which no quantitative outcome was reported. Reference lists of relevant studies were hand-searched. Searches were conducted by 2 reviewers, and a third reviewer was consulted for resolution of disagreements.

The following information/data were extracted from studies that met the inclusion criteria: the name of the first author, year of publication, number of patients in each group, age, BMI, IPSS, and quantitative outcomes.

Quality Assessment
------------------

The Newcastle-Ottawa scale was used to assess the quality of the included studies.^[@R17]^ Briefly, the instrument contains 8 items categorized into 3 dimensions: selection, comparability, and exposure (outcome). A point system is used for a semiquantitative assessment of study quality.

Outcome Measures and Data Analysis
----------------------------------

The primary outcome was the association of prostate growth rate and MS, and secondary outcomes were the associations of prostate volume, PSA level, IPSS, and maximal flow rate with MS. Data reported as median and range were converted to mean and standard deviation.^[@R18]^ Pooled mean differences were compared between groups. Heterogeneity among the studies was assessed by the Cochran Q and the *I*^2^ statistic.^[@R19]^ If either the Q statistic value of *P* was \<0.1 or *I*^2^ was \>50%, a random-effects model of analysis (DerSimonian-Laird method) was used. Otherwise, a fixed-effects model (Mantel-Haenszel method) was used. Sensitivity analyses based on the leave-one-out approach were performed to evaluate the robustness of the pooled estimates of the primary and secondary outcomes. Publication bias was not evaluated in this study because there were only 3 studies included for the primary outcome (prostate growth rate), which is insufficient to detect funnel plot asymmetry.^[@R20]^ All analyses were performed with Comprehensive Meta-Analysis software, version 2.0 (Biostat, Englewood, NJ).

ETHICS
======

This study did not involve human subjects, so informed consent was not required. In addition, no approval was required from an institutional review board.

RESULTS
=======

Literature Search and Study Characteristics
-------------------------------------------

A flow diagram of study selection is shown in Supplemental Figure 1. A total of 158 potentially relevant studies were identified, and 118 remained after duplicates were excluded. After screening by title and abstract, 31 articles were excluded, the reasons for which are shown in Supplemental Figure 1. Nine full-text articles were assessed for eligibility, and of these, 8 were included in the meta-analysis.^[@R21]--[@R28]^ The study by Aktas et al^[@R29]^ was included in the qualitative synthesis, but did not include measures appropriate for the meta-analysis.

The characteristics of the included studies were summarized in Table [1](#T1){ref-type="table"}. The 8 studies included in the meta-analysis contained a total of 3093 BPH patients, wherein 1241 had MS and 1852 did not have MS. The primary and secondary outcomes of the included studies are summarized in Supplemental Table 1.

###### 

Basic Characteristics of Included Studies
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Quality Assessment
------------------

Results of the Newcastle-Ottawa scales assessment of the included studies are shown in Table [1](#T1){ref-type="table"}. Six studies had a total score of 8 points, and 3 studies a total score of 7 points, indicating that the overall quality of the included studies was acceptable.

Primary Outcome (Prostate growth Rate)
--------------------------------------

Three studies reported prostate growth rate data.^[@R25],[@R27],[@R28]^ No significant heterogeneity was observed (Cochran Q = 3.6, *P* = 0.167; *I*^2^ = 44.1%), and thus a fixed-effects model of analysis was performed. BPH patients with MS had a significantly higher prostate growth rate than the BPH patients without MS (pooled mean difference = 0.67 mL/y, *P* \< 0.001; Figure [1](#F1){ref-type="fig"} A). The pooled mean differences of prostate growth rate with each of the studies removed were similar (range, 0.55--0.68 mL/y), and remained statistically significant (all, *P* \< 0.001), indicating good reliability in the pooled estimate (Figure [1](#F1){ref-type="fig"}B).

![Meta-analysis for prostate growth rate. (A) Pooled estimate. (B) Sensitivity analysis.](medi-95-e3243-g002){#F1}

Prostate Volume
---------------

All 8 studies reported prostate volume data.^[@R21]--[@R28]^ Significant heterogeneity was observed (Cochran Q = 70.6, *P* \< 0.001; *I*^2^ = 90.1%), and thus a random-effects model of analysis was performed. BPH patients with MS had a significantly larger prostate volume than BPH patients without MS (pooled mean difference = 6.8 mL, *P* = 0.010; Figure [2](#F2){ref-type="fig"}A). The pooled mean differences of prostate volume with each of the studies removed were similar (range, 5.27--9.27 mL), indicating acceptable reliability in the pooled estimate (Figure [2](#F2){ref-type="fig"}B).

![Meta-analysis for prostate volume. (A) Pooled estimate. (B) Sensitivity analysis.](medi-95-e3243-g003){#F2}

PSA
===

Six studies reported PSA data.^[@R21],[@R23]--[@R25],[@R27],[@R28]^ Significant heterogeneity was observed (Cochran Q = 11.8, *P* = 0.038; *I*^2^ = 57.5%), and thus a random-effects model of analysis was performed. BPH patients with and without MS had a borderline nonsignificant difference in PSA (pooled mean difference = 0.24 ng/mL, *P* = .056; Figure [3](#F3){ref-type="fig"}A). The pooled mean differences of PSA with each of the studies removed were similar (range, 0.15--0.32 ng/mL), which indicated an acceptable reliability in the pooled estimate (Figure [3](#F3){ref-type="fig"}B).

![Meta-analysis for prostatic specific antigen. (A) Pooled estimate. (B) Sensitivity analysis.](medi-95-e3243-g004){#F3}

IPSS
====

All 8 studies reported IPSS data.^[@R21]--[@R28]^ Because significant heterogeneity was observed between studies (Cochran Q = 250.8, *P* \< 0.001; *I*^2^ = 97.2%), a random-effects model of analysis was performed. There was no significant difference in IPSS score between BPH patients with and without MS (pooled mean difference = 1.58, *P* = .202; Figure [4](#F4){ref-type="fig"}A). The pooled mean differences of IPSS with each of the studies removed were similar and remained statistically nonsignificant (all, *P* \> 0.05), which indicated a good reliability in the pooled estimate (Figure [4](#F4){ref-type="fig"}B).

![Meta-analysis for International Prostate Symptom Score (IPSS). (A) Pooled estimate. (B) Sensitivity analysis.](medi-95-e3243-g005){#F4}

Maximal Flow Rate
-----------------

Four studies reported maximal flow rate data.^[@R21],[@R24]--[@R26]^ Because significant heterogeneity was observed between studies (Cochran Q = 297.8, *P* \< 0.001; *I*^2^ = 99.0%), a random-effects model of analysis was performed. There was no difference in maximal flow rate between BPH patients with and without MS (pooled mean difference = −1.41 mL/s, *P* = 0.345; Figure [5](#F5){ref-type="fig"}A). The pooled mean differences of maximal flow rate with each of the studies removed were similar (range, −1.92 to −0.27 mL/s) and remained statistically nonsignificant (all, *P* \> 0.05), indicating good reliability in the pooled estimate (Figure [5](#F5){ref-type="fig"}B).

![Meta-analysis for maximal flow rate. (A) Pooled estimate. (B) Sensitivity analysis.](medi-95-e3243-g006){#F5}

Subgroup Analysis By Region (Asia And Europe)
---------------------------------------------

Subgroup analyses by region (Asia and Europe) for prostate volume, PSA, IPSS, and maximal flow rate were performed to reduce the heterogeneity among the included studies. Four studies from Asia^[@R22],[@R24],[@R25],[@R27]^ reported prostate volumes for patients with and without MS, and the mean differences of prostate volume showed no obvious heterogeneity (Q = 3.2, df = 3, P = 0.360; *I*^2^ = 6.7%); thus, a fixed-effects model was used. The pooled estimate showed that patients with MS had higher prostate volume than those without MS (pooled mean difference = 11.96, 95% confidence interval \[CI\]: 10.94--12.98, *P* \< .001). Three studies from Europe^[@R21],[@R23],[@R26]^ reported prostate volumes for patients with and without MS, and the mean differences of prostate volume showed obvious heterogeneity (Q = 5.9, df = 2, *P* = 0.053; *I*^2^ = 66.1%); thus, a random-effects model was used. The pooled estimate showed no significant difference in prostate volume between patients with and without MS (Figure [6](#F6){ref-type="fig"}A).

![Subgroup analysis by area (Asia and Europe) (A) prostate volume (B) PSA (C) IPSS, and (D) maximal flow rate.](medi-95-e3243-g007){#F6}

Three studies from Asia^[@R24],[@R25],[@R27]^ reported PSA for patients with and without MS, and the mean differences of PSA showed minor heterogeneity (Q = 3.9, df = 2, *P* = 0.146; *I*^2^ = 48.1%); thus, a fixed-effects model was used. The pooled estimate showed that patients with MS had higher PSA than those without MS (pooled mean difference = 0.17, 95% CI: 0.00--0.34, *P* = 0.044). Two studies from Europe^[@R21],[@R23]^ showed obvious heterogeneity (Q = 7.9, df = 1, P = 0.005; *I*^2^ = 87.3%); thus, a random-effects model was used. The pooled estimate showed no significant difference in PSA between patients with and without MS (Figure [6](#F6){ref-type="fig"}B).

Four studies from Asia^[@R22],[@R24],[@R25],[@R27]^ and 3 from Europe^[@R21],[@R23],[@R26]^ reported IPSS data, and obvious heterogeneity was present in both groups (Asia: Q = 104.7, *P* \< 0.001, *I*^2^ = 97.1%; Europe: Q = 5.2, *P* = 0.075; *I*^2^ = 61.4%); thus, random-effects models were used. For both Asia and Europe, the pooled estimate of included studies showed no significant difference in IPSS between patients with and without MS (Figure [6](#F6){ref-type="fig"}C).

Two studies from Asia^[@R24],[@R25]^ reported maximal flow rate data, and there was obvious heterogeneity among studies (Q = 130.9, *P* \< 0.001; *I*^2^ = 99.2); thus, a random-effects model was used. Two studies from Europe^[@R21],[@R26]^ reported maximal flow rate data, and minor heterogeneity was present (Q = 1.9, *P* = 0.163; *I*^2^ = 48.5%); thus, a fixed-effects model was used. For both Asia and Europe, the pooled estimates showed no significant difference in maximal flow rate between patients with and without MS (Figure [6](#F6){ref-type="fig"}D).

DISCUSSION
==========

This study aimed to evaluate the association of MS with characteristics of BPH. The results showed that BPH patients with MS had a significantly higher prostate growth rate and larger prostate volume than those without MS. However, IPSS and maximal flow rate were not different between BPH patients with and without MS, and a borderline nonsignificant difference in PSA between patients with and without MS was seen. Subgroup analysis by region, however, indicated that Asian patients with MS had a larger prostate volume and PSA than those without MS, but this finding was not present in European patients. Although there have been other studies examining the association between MetS and BPH, this was the first to provide a comprehensive examination of MS and various measures of BPH.

Epidemiological studies have indicated a possible association between MS and prostatic conditions,^[@R30],[@R31]^ and some studies have shown a increased prostate growth and larger prostate volume in BPH patients with MS than those without.^[@R4]--[@R6]^ It has also been reported that MS is associated with an increased risk of LUTS as a result of prostatic enlargement.^[@R7],[@R32]^ Age-related changes in androgens have been generally accepted to be the primary factor involved in the pathogenesis of BPH.^[@R33]^

Although it is becoming apparent that there is an association with metabolic derangements and BPH, the mechanisms by which the derangements of MS may led to prostatic hyperplasia and LUTS remain to be fully elucidated. Some studies have suggested that insulin resistance and hyperinsulinemia are possible causative factors of BPH in patients with MS.^[@R5],[@R34]--[@R38]^ Other authors have suggested that chronic inflammation is the causative link between MS and LUTS and BPH. A recent systematic review of the literature by He et al^[@R39]^ suggested that the proinflammatory state present in patients with MS results in inflammatory cell infiltration of prostatic and adipose tissue with subsequent tissue remodeling and overgrowth. Prostate tissue specimens of patients with BPH have been shown to have elevated levels of inflammatory cells,^[@R39]^ and prostate volume and IPSS have been directly correlated with the level of inflammation in patients with BPH/LUTS.^[@R39]^

In another recent meta-analysis, Gacci et al^[@R15]^ included 8 studies which enrolled 5403 patients, of which 1426 had MS. Patients with MS had a significantly higher total prostate volume as compared with those without MS (+1.8 mL, 95% CI: 0.74--2.87; *P* \< 0.001); however, there was no difference in IPSS or LUTS subdomain scores between the groups. Meta-regression analysis showed that differences in total prostate volume were significantly higher in older and obese patients in contrast to those with low HDL-C concentrations. The study did not examine other measures such as prostate growth rate or maximal flow. In the present study, the report by Aktas et al^[@R29]^ did not include outcome measures appropriate for the meta-analysis. The study examined the relationship between MS, erectile dysfunction (ED), and LUTS in 106 patients with BPH, account off 31.1% (33) to whom had MS. The analysis showed a significant difference between ED groups with respect to the presence of MS (*P* = 0.032), but MS was not associated with the severity of LUTS (*P* = 0.144), nor was there a correlation between ED and LUTS severity (*P* = 0.303).

Other studies have examined the association of MS with various measures of BPH. In a study of 401 elderly Chinese men, Zhang et al^[@R24]^ found that body mass index (BMI), waist circumference, fasting glucose, glycosylated hemoglobin, triglyceride, fasting insulin, and insulin resistance assessed by homeostasis model assessment of insulin resistance (HOMA-IR) were higher and HDL-C was lower in BPH patients with MS than in those without MS. Furthermore, patients with MS had a significantly larger prostate volume (*P* = 0.000) and longer duration of LUTS (*P* = 0.006), and prostate volume was positively correlated with BMI (*P* = 0.000), fasting insulin (*P* = 0.001), HOMA-IR (*P* = 0.003) and inversely correlated with HDL-C (*P* = 0.000). In another study of 764 Chinese males older than 40 years, multivariate analysis showed that aging, cigarette smoking, lack of regular exercise, and larger prostate volume were independent predictors for moderate/severe LUTS, and risk factors for LUTS were influenced by the presence of MS.^[@R40]^ Ozden et al^[@R28]^ studied 78 patients with BPH and LUTS and found that those with MS had significantly higher median body weight, BMI, serum glucose, serum triglyceride, and PSA levels, but lower HDL-C level, compared with BPH patients without MS. The median annual total prostate growth rate (1.0 mL/y), and median annual transitional zone prostate growth rate (1.25 mL/y) were significantly higher in patients with MS than those without (0.64 mL/y and 0.93 mL/y, respectively, both *P* \< 0.05). Interestingly, a study of only Chinese patients by Zou et al^[@R41]^ found that patients with MS had a significantly higher PSA level than those without MS, which is similar to the subgroup analysis of Asian patients in our study. Thus, race may be a factor contributing to the different results in different studies.

Measures of clinical progression of BPH include quality of life, urinary retention, and risk of surgical intervention. However, these factors were not examined in the current analysis because of the 9 included studies, of which only 2 reported results of acute urinary retention, only 2 studies reported quality of life results, and only 1 study mentioned of risk of surgical intervention. Of the articles that reported rate of acute urinary retention, Pan et al^[@R25]^ found acute urinary retention in 82% of patients with MS and in 17% of patients without MS, and Cao et al^[@R27]^ reported a rate of 26.2% in patients with MS and 10.3% in patients without MS. Overall, the rate of acute urinary retention had tendency to be higher in patients with MetS than those without MS. As to quality of life, De Nunzio et al^[@R23]^ reported no difference in quality of life between patients with and without MS. Pan et al,^[@R25]^ however, reported that patients with MS had significantly higher IPSS quality of life score (4.94 ± 1.06) than did patients without MS (3.31 ± 0.95) (*P* \< 0.001).

There are limitations of this analysis that have to be considered. The definition of MS used varied between the studies, and the number of available studies and data were limited. We did not examine characteristics of MS such as BMI and waist circumference, nor the mechanisms by which MS is associated with BPH examined. Five studies used transrectal ultrasonography, 1 study used transabdominal and transrectal ultrasonography, 1 study used transabdominal ultrasonography, and 2 studies used ultrasonography without mention of the site. Study has shown that the results from transabdominal ultrasonography are not consistent with those from transrectal sonography when used to measure prostate volume,^[@R42]^ and this may have led to bias in the measurement of prostate volume.

In conclusion, the results of this meta-analysis are consistent with literature indicating that BPH patients with MS have a higher prostate growth rate and larger prostate volume than those without MS. However, measures of LUTS were not different between patients with and without MS. Further study is necessary to elucidate the association of BPH and metabolic disorder elements and the potential risk of disease progression in BPH patients with MS.

Supplementary Material
======================
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Abbreviations: BMI = body mass index, BPH = benign prostatic hyperplasia, CI = confidence interval, ED = erectile dysfunction, HDL-C = high-density lipoprotein cholesterol, HOMA-IR = homeostatic model assessment of insulin resistance, IPSS = International Prostate Symptom Score, LUTS = lower urinary tract symptoms, MS = metabolic syndrome, PSA = prostate specific antigen.
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